论文部分内容阅读
[目的]观察重组人白介素-11(rhIL-11)治疗血液肿瘤化疗后血小板低下的疗效及安全性。[方法]111例血液肿瘤化疗患者随机分为应用rhIL-11治疗组和对症治疗组。其中rhIL-11组57例,应用rhIL-111.5mg/d;对照组54例,以对症支持治疗为主。2组分别监测血小板,记录药物疗效及毒副反应。[结果]应用rhIL-11治疗组血小板最低值为48.3×109/L±25.12×109/L,对照组血小板最低值为24.4×109/L±16.51×109/L;应用rhIL-11治疗组平均血小板低下持续时间为13d,对照组为20d(P<0.05)。毒副反应为心律失常、发热、肌痛、头痛等,停药多能缓解。[结论]重组人白介素-11治疗血液肿瘤化疗后血小板低下的疗效肯定,安全性高。
[Objective] To observe the efficacy and safety of recombinant human interleukin-11 (rhIL-11) in the treatment of thrombocytopenia after hemo-tumor chemotherapy. [Method] 111 cases of patients with hematologic malignancies were randomly divided into rhIL-11 treatment group and symptomatic treatment group. In which rhIL-11 group of 57 cases, the application of rhIL-111.5mg / d; control group of 54 patients with symptomatic and supportive treatment based. Two groups were monitored for platelet, drug efficacy and side effects were recorded. [Results] The lowest value of platelet in rhIL-11 treatment group was 48.3 × 109 / L ± 25.12 × 109 / L, the lowest in control group was 24.4 × 109 / L ± 16.51 × 109 / L; Thrombocytopenia duration of 13d, control group for 20d (P <0.05). Toxic side effects of arrhythmia, fever, muscle pain, headache, etc., withdrawal can relieve. [Conclusion] Recombinant human interleukin-11 is effective and safe in treating hematopoietic tumor after thrombocytopenia after chemotherapy.